openPR Logo
Press release

Antibody Drug Conjugates Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026

09-04-2018 12:40 PM CET | Health & Medicine

Press release from: Coherent Market Insights Biotechnology

Antibody Drug Conjugates

Antibody Drug Conjugates

Antibody drug conjugate is a significant class of highly potent bio drugs envisioned as a broad therapy for treatment of cancer. Unlike chemotherapy, antibody drug conjugate are proposed to mark and kill only cancer cells. Antibody drug conjugates are compound molecules that comprise antibodies linked to a biologically active cytotoxic drug.  

Request Sample Copy of this Business Report @ https://www.coherentmarketinsights.com/insight/request-sample/181

By uniting the exclusive targeting capacities of mAB with anti-cancer drugs, ADCs allow for subtle judgment between healthy and diseased tissue. This entails that the antibody drug conjugates kill only cancer cells and ensure that other dynamic cells are less severely affected. This exceptional phenomenon of killing only cancer cells increase the importance of use of ADCs, which would indirectly boost growth of the global antibody drug conjugates market.

Commercialization of 7-10 ADCs in the following decade, would lead to revenue to surge to over US$ 10 billion over the forecast period of market

In terms of marketing, three antibody drug conjugates have received regulatory approval.  The U.S. FDA approved one of the ADC in 2001 manufactured and developed by Pfizer/Wyeth, to treat acute myelogenous leukemia. The drug was subsequently withdrawn in June 2010, leaving only two antibody drug conjugates in the market. The two drugs marketed for ADCs are Brentuximab vedotin and Trastuzumab emtansine, developed and manufactured by Seattle Genetics and Millennium/Takeda and Genentech and Roche, respectively. Around 45 antibody drug conjugates molecules are under clinical trials, with the preclinical pipeline expanding at a high rate. Of all the 45 molecules, around 25% are under Phase II or Phase III of development. Frequently used cytotoxins for antibody drug conjugates under trials include auristatin, calicheamicin, maytansine and duocarmycin. Auristatin is the dominant compound accounting for over 50% of antibody drug conjugates in clinical development. Roche has 10 compounds under clinical trials, and this is the most developed pipeline of antibody drug conjugates. Globally, 70%-80% of antibody drug conjugates manufacturing is currently outsourced. There are limited number of contract manufacturers that have high-end manufacturing equipment for development of cytotoxins.

Antibody drug conjugates market is still in its infancy, with two approved ADCs to propel the market to two digit billion dollar mark by 2020

The global antibody drug conjugates market is segmented on the basis of drug and geography. On the basis of drug, the market is divided into Adcetris and Kadcyla.

Major pharmaceutical company opt for contract manufacturer for development and manufacture of antibody drug conjugates 

Regional segmentation of the antibody drug conjugates market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. Europe accounts for the largest share in the global market mainly due to presence of many contract manufacturing companies with advanced manufacturing equipment. Lonza is one of the top contract manufacturing companies in Europe, which has operations across France and Germany, with its headquarters in Switzerland.  One of the facilities operated by the company is a deck to chemical manufacturing capabilities and develop peptides, small molecule active pharmaceutical ingredients, highly potent active pharmaceutical ingredients, cytotoxics agents, antibody drug conjugates, and microbial products. The company also offer proficiency in chemical, pharmaceutical, agrochemical and food industries by providing clients with yields such as high-class active substances, organic chemicals and intermediates.

Browse Detailed TOC @ https://www.coherentmarketinsights.com/ongoing-insight/toc/181

Large number of clinical trial molecules in pipeline to boost growth of antibody drug conjugates market

Key players operating the antibody drug conjugates market include Hoffmann-La Roche Ltd, Seattle Genetics, Takeda, ImmunoGen Inc, Pfizer Inc., Sanofi, AbbVie Inc, Cellldex Therapeutics, Synthon, and Progenics Pharmaceuticals. Major companies in the antibody drug conjugates industry are constantly working on research and development, as the market is largely untapped and offer highly lucrative growth opportunities. For instance, there are only two antibody drug conjugates available worldwide that are used to treat cancer, and there are over 40 molecules under clinical trials. Considering the alarmingly high incidence rate of cancer across the globe, the antibody conjugates market is expected to ride on a wave of positive growth in the foreseeable future. 

About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antibody Drug Conjugates Market — Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 here

News-ID: 1218809 • Views:

More Releases from Coherent Market Insights Biotechnology

Wound Care Biologics Market 2026: Global Industry Insights And Growth Analysis By Top Players - Smith & Nephew Plc., Organogenesis, Integra Lifesciences Holdings Corporation
Wound Care Biologics Market 2026: Global Industry Insights And Growth Analysis B …
Wound care biologic products facilitates in innate repair mechanisms, and involves the use of active biological agents such as animal and plant-derived active biomolecules, which exhibit antioxidant, antimicrobial, or anti-inflammatory properties. Wound care biologic dressings are increasingly being used in post surgeries and severe trauma cases as they provide moist healing environment aiding heat loss, protein and electrolyte loss for faster healing, and prevent bacterial contamination. Biologic skin substitute products
Bone Marrow Transplant Market 2018 With Major Key Players STEMCELL Technologies, Merck Millipore Corporation, Sanofi-Aventis , AllCells, ReachBio
Bone Marrow Transplant Market 2018 With Major Key Players STEMCELL Technologies, …
Bone marrow transplant is a medical procedure to replace bone marrow damaged or destroyed by disease, infection, or chemotherapy. Bone marrow transplant procedure involves transplanting blood stem cells that travel to the bone marrow where they produce new blood cells and promote growth of new marrow. Bone marrow is the spongy, fatty tissue inside human bones, which creates the different parts of blood such as red blood cells that carry
Targeted Cancer Therapies Market Future and Technological Advancement To 2026 With Key Vendors Abbott Laboratories, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline plc, AstraZeneca PLC, OncoGenex Pharmaceuticals Inc., Pfizer
Targeted Cancer Therapies Market Future and Technological Advancement To 2026 Wi …
Targeted cancer therapies are drugs which block the growth and proliferation of cancer by interfering with specific molecules such as DNA or proteins, which are involved in the growth or expansion of cancerous cells. Targeted cancer therapies differ in several ways from standard chemotherapy. Standard chemotherapy act on all rapidly dividing cancerous cells as well as normal cells, while targeted cancer therapies act on specific molecular targets that are associated
Insulin Biosimilars Market Size, Growth and SWOT Analysis by Key Players Boehringer Ingelheim, Pfizer Inc., Biocon, Merck & Co., Mylan N.V., Eli Lilly & Co., Wockhardt Limited, NOVO Nordisk A/S, Sanofi S.A
Insulin Biosimilars Market Size, Growth and SWOT Analysis by Key Players Boehrin …
Diabetes is a group of metabolic disease characterized by high blood sugar level due to inadequate secretion of insulin. Common symptoms of diabetes include increased hunger, tiredness, weight loss, and excessive thirst and urination. The prevalence of diabetes is increasing, in turn, boosting demand for insulin biosimilar. For instance, according the World Health Organization (WHO) report in 2014, globally around 422 million adults were living with diabetes and 1.5 million

All 5 Releases


More Releases for Antibody

Evolving Market Trends In The Antibody Drug Conjugates Industry: Regulation On A …
The Antibody Drug Conjugates Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Antibody Drug Conjugates Market Size During the Forecast Period? The market size for antibody drug conjugates has experienced rapid expansion in the past few years. It's projected to rise from
TIGIT Antibody Clinical Trials FDA Approval Market Size Anti TGIT Antibody Sales …
Anti TIGIT Antibodies Clinical Trials & Market Opportunity Outlook 2028 Report Highlights: • Anti TIGIT Antibodies In Clinical Trials: > 50 Antibodies • First Anti TIGIT Antibody To Get Approval Within Next 5 Years • Global Anti TIGIT Antibodies Clinical Pipeline Insight By Company, Indication and Phase • Insight On More Than 50 Anti TIGIT Antibodies In Clinical Trials • Anti TIGIT Antibodies Market Trends by Indication & Country • Global Anti TIGIT Antibodies Market Dynamics Download Report: https://www.kuickresearch.com/report-anti-tigit-antibody-anti-tigit-antibodies-fda-approved-tigit-antibody-tigit-inhibitors-tigit-drugs-approved-tigit-expression-tigit-ligand-tigit-gene In recent years, the global
Mammalian Polyclonal IgG Antibody Market, Mammalian Polyclonal IgG Antibody Mark …
"According to the research report, the global inspection machines market was valued at USD 845.21 million in 2022 and is expected to reach USD 1,437.59 million by 2032, to grow at a CAGR of 5.5% during the forecast period." Request Our Free Sample Report for Inspection Machines Market Insights and Emerging Trends @ https://www.polarismarketresearch.com/industry-analysis/inspection-machines-market/request-for-sample Report Overview Polaris Market Research, a leading global market research and consulting company, has recently published its latest report
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
The combination antibody therapy market is expected to experience significant growth in the coming years. Combination antibody therapy involves the use of two or more monoclonal antibodies (mAbs) in combination to treat various diseases, such as cancer, autoimmune disorders, and infectious diseases. Request For Free Sample Report of "Combination Antibody Therapy Market"@ https://www.persistencemarketresearch.com/samples/11740 Combination antibody therapy has several potential benefits over single-agent therapies, including increased efficacy, improved patient outcomes, and reduced toxicity.
Global Combination Antibody Therapy Market 2022: Antibody/Antibody Combination S …
Combination antibody therapy involves the use of two or more antibodies to target and treat a specific disease or condition. This type of therapy is often used in cancer treatment, as it can be more effective at targeting and killing cancer cells than single-antibody therapies. Combination antibody therapy can also be used to treat a range of other diseases and conditions, including autoimmune diseases, infectious diseases, and allergic conditions. Request For
Procalcitonin Antibody Market Report 2018: Segmentation by Type (Polyclonal Proc …
Global Procalcitonin Antibody market research report provides company profile for Ningbo Medicalsystem Biotechnology, Snibe, Vazyme Biotech, Getein Biotech, Hotgen Biotech, Lumigenex, Shanghai Medicine'nest Pharmaceutical, Thermo Fisher, Roche Diagnostics, bioMerieux, HyTest, Wondfo and Others. This market study includes data about consumer perspective, comprehensive analysis, statistics, market share, company performances (Stocks), historical analysis 2012 to 2017, market forecast 2018 to 2025 in terms of volume, revenue, YOY growth rate, and CAGR for